ATE205400T1 - Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii- spezifische mhc allopeptide - Google Patents

Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii- spezifische mhc allopeptide

Info

Publication number
ATE205400T1
ATE205400T1 AT93910671T AT93910671T ATE205400T1 AT E205400 T1 ATE205400 T1 AT E205400T1 AT 93910671 T AT93910671 T AT 93910671T AT 93910671 T AT93910671 T AT 93910671T AT E205400 T1 ATE205400 T1 AT E205400T1
Authority
AT
Austria
Prior art keywords
mammal
nonself
polymorphoic
suppression
tolerance
Prior art date
Application number
AT93910671T
Other languages
English (en)
Inventor
Howard L Weiner
David A Hafler
Charles B Carpenter
Mohamed Sayegh
Zhengi Zhang
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Application granted granted Critical
Publication of ATE205400T1 publication Critical patent/ATE205400T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
AT93910671T 1992-04-20 1993-04-20 Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii- spezifische mhc allopeptide ATE205400T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87128992A 1992-04-20 1992-04-20
US96177992A 1992-10-15 1992-10-15
US97773792A 1992-11-13 1992-11-13
US08/027,127 US5593698A (en) 1990-10-31 1993-03-05 Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
PCT/US1993/003708 WO1993020842A1 (en) 1992-04-20 1993-04-20 Suppression of proliferative response and induction of tolerance with polymorphic class ii mhc allopeptides

Publications (1)

Publication Number Publication Date
ATE205400T1 true ATE205400T1 (de) 2001-09-15

Family

ID=27487557

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93910671T ATE205400T1 (de) 1992-04-20 1993-04-20 Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii- spezifische mhc allopeptide

Country Status (13)

Country Link
US (1) US5593698A (de)
EP (1) EP0637249B1 (de)
JP (1) JPH07505892A (de)
KR (1) KR100275656B1 (de)
AT (1) ATE205400T1 (de)
AU (1) AU686101B2 (de)
BR (1) BR9306345A (de)
CA (1) CA2118502A1 (de)
DE (1) DE69330752D1 (de)
HU (1) HUT71310A (de)
IL (1) IL105472A (de)
NO (1) NO943967L (de)
WO (1) WO1993020842A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US6156306A (en) * 1994-08-17 2000-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pancreatic β-cells for allogeneic transplantation without immunosuppression
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US7348005B2 (en) * 2000-03-15 2008-03-25 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
WO2001076617A2 (en) * 2000-03-15 2001-10-18 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
EP2295067A1 (de) 2000-05-24 2011-03-16 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services E-Selectin zur Induktion der Immunotoleranz
HU229377B1 (hu) * 2000-08-21 2013-11-28 Apitope Technology Bristol Ltd Tolerogén humán peptidek
US7582313B2 (en) * 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
WO2004045376A2 (en) * 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
PL2083856T3 (pl) 2007-08-15 2011-04-29 Circassia Ltd Peptydy do odczulania na alergeny
WO2014124134A1 (en) 2013-02-07 2014-08-14 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
WO2015150492A2 (en) * 2014-04-01 2015-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) An isolated donor mhc-derived peptide and uses thereof
ES2962885T3 (es) 2015-05-15 2024-03-21 Massachusetts Gen Hospital Anticuerpos antagonistas de la superfamilia del receptor del factor de necrosis tumoral
WO2017059132A1 (en) 2015-09-29 2017-04-06 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for bcg therapy
WO2017197331A2 (en) 2016-05-13 2017-11-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364762A (en) * 1990-03-21 1994-11-15 Board Of Trustees Of The Leland Stanford Junior University Major histocompatibility complex (MHC) molecules

Also Published As

Publication number Publication date
KR950701228A (ko) 1995-03-23
US5593698A (en) 1997-01-14
BR9306345A (pt) 1998-06-30
EP0637249A4 (de) 1997-01-08
AU4108393A (en) 1993-11-18
IL105472A0 (en) 1993-08-18
NO943967D0 (no) 1994-10-19
WO1993020842A1 (en) 1993-10-28
JPH07505892A (ja) 1995-06-29
EP0637249A1 (de) 1995-02-08
KR100275656B1 (ko) 2000-12-15
HUT71310A (en) 1995-11-28
IL105472A (en) 1999-06-20
AU686101B2 (en) 1998-02-05
CA2118502A1 (en) 1993-10-28
NO943967L (no) 1994-10-19
HU9403006D0 (en) 1994-12-28
EP0637249B1 (de) 2001-09-12
DE69330752D1 (de) 2001-10-18

Similar Documents

Publication Publication Date Title
ATE205400T1 (de) Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii- spezifische mhc allopeptide
Raff et al. Mouse specific bone marrow-derived lymphocyte antigen as a marker for thymus-independent lymphocytes
PT735893E (pt) Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária
McCoy et al. 51 Chromium-release assay for cell-mediated cytotoxicity of human leukemia and lymphoid tissue-culture cells
MD970009A (en) Methods for inducing T cells tolerance to donor tissues or organs
CA2387542A1 (en) Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
GR3033894T3 (en) Preparation for activation of natural killer cells (nk-cells), said preparation containing interferon-alpha and histamine, serotonin or substances with corresponding receptor activity.
Pape et al. Kinetics of natural cytotoxicity in patients treated with human fibroblast interferon
EP0753005A4 (de) Die regulation der aktivität zytotoxischer t-zelllymphozyten mit peptiden der mhc-klasse i
HK1011503A1 (en) Immunosuppressive compositions
Gallinger et al. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice
Torelli et al. Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission
WO2000040701A3 (en) Non-myeloablative tolerogenic treatment
Billingham et al. “Adoptive” immunization of animals against skin isografts and its possible implications
Piatier-Tonneau et al. T suppressor lymphocytes regulation of adjuvant arthritis in two inbred strains of rats.
Wimer Immunosuppressive applications of PHA and other plant mitogens
Paranjpe et al. Discussion paper: specific paralysis of the antitumor cellular immune response produced by growing tumors studied with a radioisotope footpad assay
HK1021318A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
Tsokos et al. Concanavalin-induced suppressor cells: characterization on the basis of corticosteroid and radiation sensitivity.
Röllinghoff et al. Induction of secondary cytotoxic T-lymphocytes in vitro does not require cell proliferation
Allan et al. In vivo studies on suppressor lymphocyte activity following administration of Escherichia coli O138 lipopolysaccharide
WO1998052582A8 (en) Non-myeloablative tolerogenic treatment
Cupissol et al. Decrease of tumor growth in mice after intravenous thymosin-treated bone marrow cell injection
NAKAO et al. In Vitro and in Vivo Demonstration of Specific Killer T Lymphocytes to Transplanted Gliorna
Kurpisz et al. Blast transformation of lymphocytes induced by spermatozoa obtained from spermatocoele

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties